Rani Therapeutics Holdings, Inc.
RANI
$1.39
-$0.01-0.36%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.20M | 1.20M | 1.20M | 1.03M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.20M | 1.20M | 1.20M | 1.03M | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.20M | 1.20M | 1.20M | 1.03M | -- |
| SG&A Expenses | 20.11M | 21.70M | 23.11M | 23.95M | 24.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.22M | 46.76M | 48.78M | 50.63M | 51.79M |
| Operating Income | -41.02M | -45.56M | -47.58M | -49.60M | -51.79M |
| Income Before Tax | -47.60M | -52.41M | -54.54M | -56.58M | -54.92M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.60 | -52.41 | -54.54 | -56.58 | -54.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 19.28M | 22.72M | 24.74M | 26.57M | 26.75M |
| Net Income | -28.32M | -29.69M | -29.80M | -30.02M | -28.17M |
| EBIT | -41.02M | -45.56M | -47.58M | -49.60M | -51.79M |
| EBITDA | -40.04M | -44.55M | -46.55M | -48.57M | -50.80M |
| EPS Basic | -0.79 | -0.91 | -0.98 | -1.06 | -1.06 |
| Normalized Basic EPS | -0.22 | -0.23 | -0.23 | -0.24 | -0.28 |
| EPS Diluted | -0.79 | -0.91 | -0.98 | -1.06 | -1.06 |
| Normalized Diluted EPS | -0.22 | -0.23 | -0.23 | -0.24 | -0.28 |
| Average Basic Shares Outstanding | 149.09M | 131.48M | 121.26M | 113.85M | 107.07M |
| Average Diluted Shares Outstanding | 149.09M | 131.48M | 121.26M | 113.85M | 107.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |